Oncotarget

Reviews:

Current relevance of hypoxia in head and neck cancer

Marius G. Bredell _, Jutta Ernst, Ilhem El-Kochairi, Yuliya Dahlem, Kristian Ikenberg and Desiree M. Schumann

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:50781-50804. https://doi.org/10.18632/oncotarget.9549

Metrics: PDF 1894 views  |   HTML 2994 views  |   ?  


Abstract

Marius G. Bredell1, Jutta Ernst1, Ilhem El-Kochairi1, Yuliya Dahlem1, Kristian Ikenberg2 and Desiree M. Schumann1

1 Department of Cranio-, Maxillofacial and Oral Surgery, University Hospital Zürich, Zürich, Switzerland

2 Department of Pathology, University Hospital of Zürich, Zürich, Switzerland

Correspondence to:

Marius G. Bredell, email:

Keywords: hypoxia, head and neck cancer, oral cancer, biomarkers

Received: July 14, 2015 Accepted: April 28, 2016 Published: May 21, 2016

Abstract

Head and Neck cancer (HNC) is a complex mix of cancers and one of the more common cancers with a relatively poor prognosis. One of the factors that may assist us in predicting survival and allow us to adjust our treatment strategies is the presence of tumor hypoxia. In this overview we aim to evaluate the current evidence and potential clinical relevance of tumor hypoxia in head and neck cancer according to an extensive search of current literature.

An abundance of evidence and often contradictory evidence is found in the literature. Even the contradictory evidence and comparisons are difficult to judge as criteria and methodologies differ greatly, furthermore few prospective observational studies exist for verification of the pre-clinical studies. Despite these discrepancies there is clear evidence of associations between prognosis and poor tumor oxygenation biomarkers such as HIF-1α, GLUT-1 and lactate, though these associations are not exclusive. The use of genetic markers is expanding and will probably lead to significantly more and complex evidence. The lack of oxygenation in head and neck tumors is of paramount importance for the prediction of treatment outcomes and prognosis. Despite the wide array of conflicting evidence, the drive towards non-invasive prediction of tumor hypoxia should continue.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9549